Published in Leuk Res on June 01, 2017
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood (2009) 2.51
Mast cell leukemia. Blood (2012) 1.42
Comprehensive mutational profiling in advanced systemic mastocytosis. Blood (2013) 1.35
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med (2016) 1.16
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol (2014) 1.14
Mast cell leukemia: a report of ten cases. Ann Hematol (2008) 1.09
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Res (2017) 0.83
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica (2017) 0.82
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia (2016) 0.82
ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. Br J Haematol (2015) 0.81
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res (2016) 0.75
Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res (2014) 0.75
Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res (2017) 0.75
Clonal chromosomal abnormalities appearing in Philadelphia negative metaphases during CML treatment. Blood (2017) 0.75
JAK2V617F detection and allele burden measurement in saliva vs. peripheral blood in patients with myelofibrosis. Leuk Res (2017) 0.75
Validation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples. Cancer Genet (2017) 0.75